Back to results
US 9,068,230 B2Granted
Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
AssigneeGenentech, Inc.
InventorsDavid Dornan, Bart Burington
Life of this patent
Estimating the term…
Abstract
The invention provides methods and kits useful for predicting or assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies.
Claims16
A method for treating a human subject having a B-cell lymphoma, comprising the steps of:
- (a) performing a nucleic acid-based detection assay to detect the expression level of the UAP1 RNA transcript in a sample comprising B lymphoma cells obtained from the human subject;
- (b) determining that the B lymphoma cells from the human subject express the UAP1 RNA transcript at an increased level compared to a reference level;
- (c) determining that the human subject is responsive to an anti-CD40 antibody treatment based on the increased level of the UAP1 RNA transcript in the B lymphoma cells as compared to the reference level;
- and
- (d) administering an effective amount of an anti-CD40 antibody to the human subject expressing the increased level of the UAP1 RNA transcript in the B lymphoma cells, thereby treating B-cell lymphoma in the human subject.
2 more elements
Dependencies are inferred from the claim text.